These substances are related to the DEA’s interest in researching hallucinogenic controlled products for clinical tests and research. The DEA asserts that it wants to support the regulated trials of schedule 1 substances, so increasing the production quota explains why this move is essential. The DEA also wants to research the requirements for manufacturing new drugs and the kind of impact marijuana has on the body. These steps are taken to work towards the Food and Drug Administration’s possibilities to approve a new drug.
Save dough on the good-good without breaking a sweat. The post Why you should shop…
Quantity vs. Frequency - One of the most significant distinctions between medical and recreational cannabis…
At least 10 states and Amsterdam have new stores for you. The post Grand Openings:…
Welcome all Stargazers! November promises a month of celestial buoyancy even as the days and…
According to fresh data from the US National Institute on Drug Abuse, young women have…
Many states have enacted strict privacy laws that prevent dispensaries from sharing customer data without…